The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...
With an expiration date still more than a year away, here's what the latest details reveal.
Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million ...
The company said that the FDA hold has impacted two experimental gene therapies, RGX-111 and RGX-121. ・REGENXBIO added that ...
FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41 ...
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
Hosted on MSN
Update: The FDA missed its self-imposed deadline to ban formaldehyde in hair straighteners
UPDATE (January 5, 2026): The future of the Food and Drug Administration (FDA)'s proposed ban on hair-straightening products containing formaldehyde is now uncertain, as the organization just missed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results